A man has revealed he has been injected with the Ebola virus on purpose in a bid to fight the deadly disease. Peter Hubbard said he hopes the small risk he is taking could help create a vaccine to prevent further outbreaks of the disease, which has claimed thousands of lives in West Africa. Speaking from his apartment in Alexandria, Virginia, Mr Hubbard, a consultant who specialises in natural gas and peer markets, said: "I get a lot of satisfaction out of the fact that this could potentially develop into a viable vaccine that prevents another outbreak. It might not help out with the current outbreak but it could prevent a future one, so that's a real plus in my book." Mr Hubbard, 35, is one of 20 people taking part in clinical trials for a vaccine at the National Institutes of Health (NIH) in the United States. The vaccine he is trialling, co-developed by GlaxoSmithKline and the NIH, consists of a common cold virus, adenovirus, which has been engineered to carry TWO genes of the Ebola virus. Animal testing has shown that when the adenovirus infects cells, the Ebola genes produce harmless proteins that stimulate the immune system to produce antibodies to the deadly disease. Despite being injected with parts of the virus on September 9, Mr Hubbard revealed that he felt so healthy he has even taken part in a marathon. He said: "I feel great, yeah. In fact, I couldn't tell where the injection site was thirty minutes after it. I ran a marathon on Sunday. I'm alive and kicking." Hubbard also revealed it was the fifth vaccine study he has participated in, having previously been a test subject for vaccines for malaria, HIV, chickungunya and H1N1. Peter Hubbard Vaccine: Peter Hubbard hopes he will help ensure the virus is contained. He said: "I do have a joke that, that with all of these vaccine trials that I've done, that if plague and pestilence were to sweep throughout the land, I'd be the last man standing. "But honestly, I'm not worried about an Ebola outbreak because I've taken the time to inform myself and I realise that there's very low risk for that." Around 5,000 people have been killed by Ebola, mostly in Liberia, Sierra Leone and Guinea - the three African nations hardest hit by the virus, which spreads through direct contact with the bodily fluids of an infected person. The GSK vaccine study is being fast-tracked and, if the results are successful, the company plans to build a stockpile of up to 10,000 doses for emergency deployment.
Man injects himself with Ebola on purpose
Health & Science
By Mirror| 9yrs ago | 2 min read
.
Trending Now
- Renowned activist Asunta Wagura welcomes twins at 60
- Renowned activist Asunta Wagura welcomes twins at 60
- Night sweats: Six possible underlying health concerns
- Doctors skip presser as State confident of a deal
- Cleft charity firms to establish 40 solar pediatric theatres by next year
- Ogolla's wedding ring handed over to family
- Reflection: 34 years later, Asunta Wagura writes 'goodbye to HIV...'
- Pharmacists want chemists selling prescription drugs to minors punished
- Colonel Keitany died on his wedding anniversary
- Military top shots likely to succeed CDF Ogolla
.
Popular this week
- Renowned activist Asunta Wagura welcomes twins at the age of 60
- Night sweats: Six possible underlying health concerns
- Cleft charity firms to establish 40 solar pediatric theatres by next year
- Doctors skip presser as State confident of a deal
- Lt Gen Charles Kahariri named the new Vice Chief of Defence Forces on March 8
- Reflection: 34 years later, Asunta Wagura writes 'goodbye to HIV...'
- Sitting for hours linked to early death - exercise incapable of reversing effects
- Pharmacists want chemists selling prescription drugs to minors punished
- Former KTN anchor Michael Oyier is dead
- Despite the pain and rejection, endometriosis has made me stronger
Previous article
.
Similar Articles
.
Latest Articles
Health & Science
By Alex Kiarie
2024-04-23 00:00:00
Health & Science
2024-04-23 00:00:00
Health & Science
By Nancy Nzau
2024-04-22 11:00:00
Health & Science
By Ryan Kerubo
2024-04-22 00:00:00
.